Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9078 USD 0.81% Market Closed
Market Cap: 167.5m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nektar Therapeutics
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
PP&E Gross
$12.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
PP&E Gross
$20.5B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
PP&E Gross
$8.3B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
7%
Pfizer Inc
NYSE:PFE
PP&E Gross
$19B
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
PP&E Gross
$23.4B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
PP&E Gross
$16.2B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
7%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
167.5m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6997 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's PP&E Gross?
PP&E Gross
12.4m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's PP&E Gross amounts to 12.4m USD.

What is Nektar Therapeutics's PP&E Gross growth rate?
PP&E Gross CAGR 1Y
-68%

Over the last year, the PP&E Gross growth was -68%.

Back to Top